Introduction {#s1}
============

Good glycemic control is considered to be one of the cornerstones in the management of type 2 diabetes. In addition to lifestyle modification, most patients need pharmacological treatment, and most international guidelines recommend metformin as first-line therapy \[[@R01]\]. Metformin remains the optimal antidiabetic drug for initial monotherapy due to its low cost, proven safety record, weight neutrality, and possible improvement of cardiovascular outcomes \[[@R04]\]. The Japan Diabetes Society guideline does not make any specific recommendations about first-line therapy \[[@R05]\], but states that appropriate drugs should be selected according to the characteristics of each patient. Insulin sensitizers such as metformin or thiazolidinedione derivatives are preferred for obese patients, while insulin secretagogues such as sulfonylureas or glinides are recommended for non-obese patients. Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors have been recommended irrespective of body mass index (BMI) because of a good safety profile, low frequency of hypoglycemia, and ease of use in elderly patients.

Among several new treatments introduced over the past few years, the new class of oral "incretin" drugs known as DPP-4 inhibitors is the most notable. DDP-4 inhibitors reduce the blood glucose level by inactivating DPP-4, an enzyme that metabolizes glucagon-like peptide-1 (GLP-1), which is a gastrointestinal hormone that augments insulin release in response to a rise of blood glucose. Sitagliptin was the first DPP-4 inhibitor, being marketed in the United States in 2007 and in Japan in 2009. Sitagliptin was followed by vildagliptin and alogliptin, but it remains most widely used in Japan and worldwide among these DPP-4 inhibitors. If a patient's HbA1c is ≥ 7% despite administration of sitagliptin, we should move to the next step of treatment, but the optimum next step is unclear. Switching from sitagliptin to another DPP-4 inhibitor, such as vildagliptin or alogliptin, might be one option.

Direct comparison of the effects of vildagliptin and alogliptin on glycemic control has not yet been performed in Japanese patients. Therefore, we examined the effects of vildagliptin (50 mg twice daily) and alogliptin (20 mg twice daily) on the plasma glucose level and HbA1c in patients with type 2 diabetes who had inadequate glycemic control despite treatment with the usual dose of sitagliptin (50 mg daily). In addition, patients who could not achieve the target HbA1c level of \< 7.0% with vildagliptin or alogliptin treatment were switched to high-dose sitagliptin therapy (100 mg daily) and the effect on glycemic control was determined.

Subjects and Methods {#s2}
====================

Subjects {#s2a}
--------

Patients with type 2 diabetes attending Yokohama City University Medical Center were enrolled in this study. The inclusion criteria were men and women aged from 20 to 85 years who showed inadequate glycemic control (HbA1c from 7% to 9.5%) on treatment with sitagliptin (50 mg daily). The exclusion criteria were as follows: 1) a history of diabetic ketoacidosis or diabetic coma within 6 months prior to study entry, 2) a history of cardiac failure, 3) surgery scheduled during the observation period of this study, 4) severe infection or severe trauma, 5) pregnant or breast-feeding female patients, 6) renal insufficiency (serum creatinine \> 132.6 μmol/L or estimated glomerular filtration rate (e-GFR) \< 30 mL/min), 7) severe liver dysfunction, 8) insulin therapy, 9) a history of a hypersensitivity to exenatide or liraglutide, and 10) other patients who were judged to be inappropriate for this study by the attending physician.

Study protocol {#s2b}
--------------

This was a single-center randomized clinical trial. Recruitment and follow-up were performed from December 2011 to April 2013 according to the above-mentioned criteria. Patients were randomly assigned (1:1) to either the alogliptin group or the vildagliptin group with stratification by baseline HbA1c (\< 7.5% vs. ≥ 7.5%), age (\< 60 years vs. ≥ 60 years), and sex. Nineteen patients were assigned to the vildagliptin group and 16 to the alogliptin group. Their treatment was switched from sitagliptin (50 mg once daily) to alogliptin at 25 mg once daily in the alogliptin group or vildagliptin at 50 mg twice daily in the vildagliptin group. If the target HbA1c level of \< 7% was not achieved after 3 months, alogliptin or vildagliptin was switched to high-dose sitagliptin (100 mg daily). If HbA1c was \< 7%, the same treatment was continued for another 3 months. At 3 and 6 months after randomization, we determined the HbA1c level, plasma glucose level, and response rate (RR; the percentage of patients achieving the target HbA1c \< 7.0% or plasma glucose \< 130 mg/dL).

Blood samples were collected from an antecubital vein before starting treatment and every 4 weeks during the study. HbA1c was measured by high-performance liquid chromatography and the plasma glucose level was measured by the glucose oxidase method.

This study was approved by the Ethics Committee of Yokohama City University School of Medicine (Yokohama, Japan) and its affiliated hospital. All of the patients provided written informed consent. This study was registered with UMIN (UMIN-000010445).

Statistical analysis {#s2c}
--------------------

We calculated the required sample size with the standard formula for a one-sided, one-sample Chi-square test and found that a sample of 29 patients would provide 80% power to reject the null hypothesis (a control rate of 20%, at 3 months), assuming a control rate of 40%. Considering possible loss to follow-up, the target sample size was set at 35 patients per group. Baseline characteristics were summarized as frequencies for categorical variables and as the mean and standard deviation (mean ± SD) for continuous variables. Comparisons between two categories were performed with the paired Student's *t*-test, while changes in continuous variables were examined by using repeated measures ANOVA and/or the Wilcoxon signed-rank test. Comparisons between groups were performed by using the *t*-test, Chi-square test, or Fisher's exact test. Imputation was not performed for missing data. The level of significance was set as P \< 0.05 (two-sided). All statistical analyses were performed with SPSS version 22.0 for Windows (IBM Corporation, NY, USA).

Results {#s3}
=======

A total of 35 patients were randomized, with 19 patients assigned to the vildagliptin group and 16 patients to the alogliptin group, while 15 and 13 patients completed the study, respectively ([Fig. 1](#F1){ref-type="fig"}). There were no significant between-group differences of baseline patient characteristics, including the age, sex, BMI, HbA1c, and renal function ([Table 1](#T1){ref-type="table"}). Treatment with vildagliptin for 12 weeks reduced mean HbA1c, although not significantly (8.012% vs. 8.02%, P = 0.7). In the 15 subjects from the vildagliptin group whose HbA1c was not \< 7%, treatment was switched from vildagliptin to high-dose sitagliptin (100 mg daily), but HbA1c was slightly higher at 24 weeks (8.3%). During treatment with alogliptin for 12 weeks, mean HbA1c increased significantly (8.0% vs. 8.3%, P \< 0.05). After the 13 subjects from the alogliptin group whose HbA1c was not \< 7% were switched to high-dose sitagliptin, HbA1c returned to the baseline level of 8.0%, showing a significant decrease (P \< 0.05). Comparison between the vildagliptin and alogliptin groups showed that the reduction of HbA1c was significantly greater with vildagliptin (P = 0.008).

![Assessment, randomization, and follow-up of the study patients.](jocmr-09-567-g001){#F1}

###### Clinical and Laboratory Characteristics at Baseline, 12 Weeks, and 24 Weeks of Treatment With Vildagliptin or Alogliptin

                  Vildagliptin   Alogliptin                                                  
  --------------- -------------- -------------- -------------- -------------- -------------- --------------
  Age             63.2 ± 13.5                                  65.1 ± 12.0    60.4 ± 12.9    
  Male            10                                           9                             
  Female          9                                            7                             
  Height (cm)     162.8 ± 10.1                                 159.3 ± 9.5                   
  Weight (kg)     65.4 ± 13.3    68.6 ± 13.2    67.2 ± 16.3    59.4 ± 11.2    60.4 ± 12.9    60.2 ± 12.1
  BMI (kg/m^2^)   24.6 ± 4.4                                   23.1 ± 3.5                    
  PG (mg/dL)      175.5 ± 54.4   179.1 ± 73.4   172.2 ± 54.5   175.4 ± 50.9   195.3 ± 55.0   189.3 ± 32.4
  HbA1c (%)       8.0 ± 0.5      8.0 ± 0.8      8.3 ± 0.7      8.0 ± 0.5      8.31 ± 0.7\*   8.0 ± 0.8†

\*P = 0.05, data compared with baseline values using the *t*-test. †P = 0.05, data compared with 12 weeks values using the t-test.

Changes in plasma glucose were consistent with those of HbA1c. Vildagliptin treatment did not cause a significant change in the plasma glucose level from baseline to 12 weeks (175.5 ± 54.4 mg/dL vs. 179.1 ± 73.4 mg/dL). After switching to high-dose sitagliptin for 12 weeks, there was also no significant change in plasma glucose. In the alogliptin group, the plasma glucose level increased from 175.4 ± 50.9 mg/dL to 195.3 ± 55.0 mg/dL after 12 weeks, but this change was not significant. After switching from alogliptin to high-dose sitagliptin treatment for 12 weeks, plasma glucose improved to 189.3 ± 32.4 mg/dL. Comparison between the vildagliptin and alogliptin groups showed no significant difference in plasma glucose levels at 12 weeks (P = 0.937). Body weight was unchanged during the observation period and showed no significant difference between the two groups.

The RR for achieving the target HbA1c level \< 7.0% at 12 weeks was not significantly different between the alogliptin and vildagliptin groups, but the RR for achieving the target plasma glucose level \< 130 mg/dL at 12 weeks was significantly higher in the vildagliptin group (P = 0.047) ([Table 2](#T2){ref-type="table"}).

###### The Response Rate (RR) of Achieving the Goal Proportion of Patients Who Achieved Target Glycemic Control

                                                                    Alogliptin (N = 16)   Vildagliptin (N = 19)   P value
  ----------------------------------------------------------------- --------------------- ----------------------- ---------
  Proportion of patients who achieved HbA1c \< 7.0% at 12 weeks     1 (6.3%)              2 (10.5%)               1.000
  Proportion of patients who achieved PG \< 130 mg/dL at 12 weeks   1 (6.3)               7 (36.8%)               0.047
  Change to sitagliptin                                             13 (81.2%)            15 (78.9%)              
  Proportion of patients who achieved HbA1c \< 7.0% at 24 weeks     3 (9.1%)                                      
  Proportion of patients who achieved PG \< 130 mg/dL at 24 weeks   1 (3.0%)                                      

Discussion {#s4}
==========

The present study was the first to directly compare efficacy between sitagliptin and two other DPP-4 inhibitors (vildagliptin and alogliptin) in patients with type 2 diabetes. There was no significant change in HbA1c after switching from sitagliptin to vildagliptin. On the other hand, there was a significant increase in HbA1c after switching from sitagliptin to alogliptin, while HbA1c returned to baseline when patients subsequently switched to high-dose sitagliptin. In addition, the RR for achieving the target HbA1c \< 7.0% at 12 weeks was not significantly different between the vildagliptin and alogliptin groups, but the RR for achieving the target plasma glucose \< 130 mg/dL was significantly higher in the vildagliptin group. These results suggest that the glucose-lowering effect of vildagliptin was significantly stronger than that of alogliptin.

A meta-analysis has shown that the efficacy of DPP-4 inhibitors for reducing HbA1c was higher in Asian patients with type 2 diabetes than in other ethnic groups and it seems that BMI differences across ethnic groups may influence the relative HbA1c-lowering effect of these inhibitors \[[@R06]\]. Therefore, DPP-4 inhibitors are often selected as first-line therapy in Japan. Among the available DPP-4 inhibitors, sitagliptin is most widely used in Japan as well as elsewhere in the world. When a patient's HbA1c remains around 7% or higher despite treatment with sitagliptin at 50 mg/day, the next step is usually to start combination therapy. If the glucose-lowering effect of different DPP-4 inhibitors varies, switching from sitagliptin to another DPP-4 inhibitor could also be an option. However, direct comparison of the glucose-lowering effect of DPP-4 inhibitors has not been performed before. Messori et al compared the therapeutic equivalence of five DPP-4 inhibitors by developing a standard Forest plot that incorporated information previously reported in randomized trials and reported that (in combination with metformin) linagliptin, saxagliptin, sitagliptin, and vildagliptin showed an equivalent effect, whereas alogliptin did not satisfy the equivalence criterion \[[@R07]\].

Direct comparison of the effects of vildagliptin and alogliptin on glycemic control has not been performed before in Japanese patients. In the present study, patients were switched from sitagliptin to vildagliptin or alogliptin, and HbA1c at 12 weeks was significantly lower in the vildagliptin group than in the alogliptin group. Switching from sitagliptin to vildagliptin and subsequently switching to high-dose sitagliptin had no significant effect on HbA1c. In contrast, HbA1c increased after switching from sitagliptin to alogliptin, but then returned to baseline after subsequently switching to high-dose sitagliptin. These results suggest that the glucose-lowering effects of sitagliptin and vildagliptin might be similar and that both drugs have a significantly greater hypoglycemic effect than alogliptin, which are compatible with the results of previous studies performed in Japan \[[@R08]\].

There have been a few studies comparing the effects of different DPP-4 inhibitors. A marked increase in GLP-1 and suppression of glucagon secretion were observed in the interprandial period when patients were switched from twice daily vildagliptin treatment to sitagliptin at 100 mg once daily (P \< 0.01) \[[@R11]\]. It was also reported that an increase in BMI contributes to attenuation of the HbA1c-lowering effect of sitagliptin, but not vildagliptin, in Japanese type 2 diabetic patients \[[@R12]\]. In the present study, the BMI of the subjects was not so high, which might be the reason why the HbA1c-lowering effect of sitagliptin (50 mg/day) and vildagliptin (100 mg/day) showed no significant difference.

*In vitro* data about the DPP-4 inhibitory activity of the three drugs used in this study have not been consistent \[[@R13]\]. We found that the glucose-lowering effect of alogliptin was slightly weaker than that of sitagliptin or vildagliptin. It has been reported that sitagliptin dose-dependently inhibits plasma DPP-4 activity over 24 h, increases the levels of active GLP-1 and GIP, increases the insulin/C-peptide ratio, decreases the glucagon level, and reduces glycemic excursion after the OGTT \[[@R16]\]. Vildagliptin was reported to maintain a high GLP-1 level and suppress glucagon for over 14 h \[[@R17]\]. However, it is not clear how effectively (for how long and to what extent) alogliptin suppresses glucagon, although alogliptin has strong DPP-4 inhibitory activity and maintains a high GLP-1 concentration. Thus, it is possible that the suppressive effect of alogliptin on glucagon may be weaker or shorter compared with sitagliptin or vildagliptin.

This study showed that the glucose-lowering effects of the three DPP-4 inhibitors were slightly different. However, switching from one DPP-4 inhibitor to another, especially from sitagliptin to alogliptin, might not be a useful treatment option because the RR for achieving the target HbA1c \< 7.0% was very low. In addition, increasing the dose of sitagliptin from 50 to 100 mg did not seem to be useful, in agreement with a previous report \[[@R18]\]. Therefore, if the target HbA1c is not reached by treatment with a DPP-4 inhibitor, adding a different oral hypoglycemic drug, GLP-1 agonist, or insulin might be the next step to take.

Limitations {#s4a}
-----------

There were some limitations of this study that should be noted. First, the sample size was small and the study period was short. Second, the relative efficacy of sitagliptin (50 mg daily) and vildagliptin (100 mg daily) could not be determined, as this study was not powered to assess small differences in efficacy. Third, changes in the serum levels of GLP-1 and glucagon were not examined.

Conclusions {#s4b}
-----------

The glucose-lowering effects of three DPP-4 inhibitors (vildagliptin, alogliptin, and sitagliptin) were different, with the effects of vildagliptin and sitagliptin apparently being significantly stronger than that of alogliptin.
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